Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Inflammation may hijack the Brain's reward system in depressed women

NCT ID NCT03848715

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how inflammation affects the brain's reward system in 40 younger women with depression. Participants received either an endotoxin (to trigger temporary inflammation) or a placebo, and researchers measured changes in how they responded to rewards like money or smiling faces. The goal was to better understand the link between inflammation and depression, which could help identify new ways to intervene.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Endotoxin
What this could lead to
If successful, this research could point toward new ways to prevent or treat depression by targeting inflammation-related reward system changes.
What could go wrong
This is a small, early-phase study (40 participants) focused on understanding mechanisms, not testing a treatment. Results may not lead directly to therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

40 people

The number who actually took part.

Started

Oct 2019

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 44 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants will be required to be in good general health (as evaluated during the phone and in-person baseline session) * Participants will be biologically female and premenopausal (as evaluated by self report). * Participants will 25-44 years of age. Exclusion Criteria: * Presence of chronic mental or physical illness * History of allergies, autoimmune, liver, or other severe chronic diseases, * Current and regular use of prescription medications such as steroids, non-steroid anti-inflammatory drugs, aspirin, immune modifying drugs, opioid analgesics, statins, antihypertensive drugs, anti-arrhythmic drugs, and antidepressant medications (none in the last 6 months). * Nightshift work or time zone shifts (\> 3hrs) within the previous 6 weeks * Previous history of fainting during blood draws. * Presence of co-morbid medical conditions not limited to but including cardiovascular (e.g., history of acute coronary event, stroke) and neurological diseases (e.g., Parkinson's disease), as well as pain disorders; * Presence of comorbid inflammatory disorders such as rheumatoid arthritis or other autoimmune disorders; * Presence of an uncontrolled medical condition that is deemed by the investigators to interfere with the proposed study procedures, or to put the study participant at undue risk; * Presence of chronic infection, which may elevate proinflammatory cytokines; * Presence of an acute infectious illness in the two weeks prior to an experimental session. * Current Axis I psychiatric disorders as determined by the Research Version of the Structured Clinical Interview including a current major depressive disorder and substance dependence * Lifetime history of suicide attempt or inpatient psychiatric admission. * Current history of sleep apnea or nocturnal myoclonus; Phase-shift disorder, which will be identified by the Structured Clinical Interview and the Duke Structured Interview for Sleep Disorders * Current smoking or excessive caffeine use (\>600 mg/day) because of the known effects on proinflammatory cytokine levels; * Evidence of recreational drug use from urine test. * Body mass index \> 35 because of the effects of obesity on proinflammatory cytokine activity * Any clinically significant abnormality on screening laboratory tests * Clinically significant abnormalities in electrocardiogram

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anhedonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Anhedonia Depression depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Norman Cousins Center for Psychoneuroimmunology, University of California, Los Angeles

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.